GlassScriptPhysician profile
Eyan P Roth
NPI 1689241440
$909.61
in general payments reported to CMS, 2019-2025
19 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $129 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $165.68 | 2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $153.34 | 2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $93.73 | 2024-2025 | |
| Abbvie INC. | $77.31 | 2024-2025 | |
| Medtronic, INC. | $68.24 | 2025 | Intellis Adaptivestim |
| Amgen INC. | $59.76 | 2024-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $41.46 | 2025 | Ozempic, Rybelsus |
| Baxter Healthcare | $30.12 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $26.33 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.10 | 2025 | Caplyta |
| Insulet Corporation | $21.57 | 2025 | Omnipod |
| Globus Medical, INC. | $20.85 | 2025 | Senza |
| Corcept Therapeutics | $20.52 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $20.33 | 2025 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $19.76 | 2025 | Ajovy |
| Phathom Pharmaceuticals, INC. | $15.19 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $14.20 | 2025 | Arexvy, Shingrix, Bexsero |
| Currax Pharmaceuticals LLC | $13.62 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eyan Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.